Protocol Ledger

NCT05650229 · Phase II · RECRUITING

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Interventional Phase II clinical trial protocol NCT05650229 sponsored by Pharming Technologies in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-13 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05650229
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05650229
Protocol FieldVerified Registry Value
NCT IdentifierNCT05650229
Consolidated Lead SponsorPharming Technologies
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2022-12-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI